Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab + lenalidomide + dexamethasone in high-risk smoldering multiple myeloma
NCT04270409Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jun 2020
- Primary completion
- Oct 2030
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of isatuximab in smoldering multiple myeloma (SMM) (2 arms), sponsored by Sanofi. Primary endpoints: Treatment-emergent adverse events at 63 months, Plasma concentration of isatuximab and 2 more. Started Jun 2020; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT04270409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04270409.